Iron + Folic Acid + Vitamin A + Vitamin C + Zinc interactions
Checked as Iron + Folic acid + Vitamin A in this data source.
Full monograph for Iron + Folic Acid + Vitamin A + Vitamin C + ZincCheck it against another medicine
Medicines
573 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acitretinvia Vitamin A | Major | Synergy | Concomitant use of a retinoid with vitamin A or other retinoids may result in hypervitaminosis A and additive toxicities. Patients may be at increased risk for… | 5 sources — open the full entry |
| Capecitabinevia Folic acid | Major | Synergy | Coadministration with folate therapy may potentiate the pharmacologic effects of 5-fluorouracil (5-FU). The exact mechanism of interaction is unknown. Although… | 9 sources — open the full entry |
| Clindamycin + Tretinoinvia Vitamin A, Folic acid | Major | Synergy · Unknown | Concomitant use of a retinoid with vitamin A or other retinoids may result in hypervitaminosis A and additive toxicities. Patients may be at increased risk for…3 documented mechanisms | 5 sources — open the full entry |
| Doxycycline Hydrochloridevia Iron, Vitamin A, Folic acid | Major | Absorption · Synergy · Unknown | Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…3 documented mechanisms | 37 sources — open the full entry |
| Fluocinolone Acetonide + Hydroquinone + Tretinoinvia Vitamin A, Folic acid | Major | Synergy · Unknown | Concomitant use of a retinoid with vitamin A or other retinoids may result in hypervitaminosis A and additive toxicities. Patients may be at increased risk for…2 documented mechanisms | 5 sources — open the full entry |
| Fluorouracilvia Folic acid | Major | Synergy | Coadministration with folate therapy may potentiate the pharmacologic effects of 5-fluorouracil (5-FU). The exact mechanism of interaction is unknown. Although… | 9 sources — open the full entry |
| IsotretinoinOralTopicalvia Vitamin A | Major | Synergy | Concomitant use of a retinoid with vitamin A or other retinoids may result in hypervitaminosis A and additive toxicities. Patients may be at increased risk for… | 5 sources — open the full entry |
| Minocycline Hydrochloridevia Iron, Vitamin A | Major | Absorption · Synergy | Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…2 documented mechanisms | 37 sources — open the full entry |
| Oxytetracyclinevia Iron, Vitamin A | Major | Absorption · Synergy | Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…2 documented mechanisms | 37 sources — open the full entry |
| Oxytetracycline + Polymixin B Sulphatevia Iron, Vitamin A | Major | Absorption · Synergy | Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…2 documented mechanisms | 37 sources — open the full entry |
| Tetracycline Hydrochloridevia Iron, Vitamin A, Folic acid | Major | Absorption · Synergy · Unknown | Concomitant use of vitamin A or related compounds (i.e., retinoids) with tetracyclines may increase the risk of pseudotumor cerebri, also known as benign…3 documented mechanisms | 37 sources — open the full entry |
| Tretinoin (Oral)via Vitamin A, Folic acid | Major | Synergy · Unknown | Concomitant use of a retinoid with vitamin A or other retinoids may result in hypervitaminosis A and additive toxicities. Patients may be at increased risk for…2 documented mechanisms | 5 sources — open the full entry |
| Alendronic acidvia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to…2 documented mechanisms | 9 sources — open the full entry |
| Alendronic Acid + Vitamin D3via Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Products containing aluminum, calcium, magnesium and other polyvalent cations such as antacids or vitamin with mineral supplements are likely to…2 documented mechanisms | 9 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxidevia Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethiconevia Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing…2 documented mechanisms | 12 sources — open the full entry |
| Aluminium Oxide + Magnesium Trisilicatevia Iron | Moderate | Absorption | The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The… | 12 sources — open the full entry |
| Baloxavir Marboxilvia Iron | Moderate | Absorption | Coadministration with polyvalent cation-containing products may decrease the plasma concentrations and therapeutic efficacy of baloxavir. The proposed… | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocainevia Iron, Folic acid | Moderate | Antagonism · Unknown | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12…4 documented mechanisms | 3 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin Evia Iron | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Calcium acetate + Magnesium carbonatevia Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Calcium Carbonatevia Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin Cvia Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3via Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3via Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multimineralsvia Iron | Moderate | Absorption | INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing… | 12 sources — open the full entry |
| Carbamazepinevia Folic acid | Moderate | Antagonism | Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair… | 26 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged releasevia Iron | Moderate | Absorption | INTERVAL: The oral bioavailability and pharmacologic effects of levodopa and carbidopa may be decreased during concurrent administration with iron-containing… | 5 sources — open the full entry |
| Cefdinirvia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: The oral bioavailability of cefdinir may be significantly decreased by concomitant administration of iron preparations. The proposed mechanism is…2 documented mechanisms | 2 sources — open the full entry |
| Chloramphenicol (Oral)via Iron, Folic acid | Moderate | Antagonism · Unknown | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12…2 documented mechanisms | 3 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloridevia Iron, Folic acid | Moderate | Antagonism · Unknown | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12…3 documented mechanisms | 3 sources — open the full entry |
| CiprofloxacinbaseOphthalmicvia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 32 sources — open the full entry |
| Ciprofloxacin + Dexamethasonevia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…3 documented mechanisms | 32 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetatevia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 32 sources — open the full entry |
| Clobetasol Propionate + Ofloxacin + Ornidazole + Terbinafinevia Iron, Vitamin A, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…6 documented mechanisms | 32 sources — open the full entry |
| Deferipronevia Iron | Moderate | Absorption | INTERVAL: Deferiprone has the potential to bind polyvalent cations such as aluminum, iron and zinc, which may reduce its effectiveness. However, concurrent use… | 1 sources — open the full entry |
| Delafloxacinvia Iron | Moderate | Absorption | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics… | 32 sources — open the full entry |
| Dexamethasone + Chloramphenicolvia Iron, Folic acid | Moderate | Antagonism · Unknown | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12…3 documented mechanisms | 3 sources — open the full entry |
| Dexamethasone + Levofloxacinvia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 32 sources — open the full entry |
| Dexlansoprazolevia Iron | Moderate | Absorption | The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent… | 12 sources — open the full entry |
| Eltrombopag Olaminevia Iron | Moderate | Absorption | INTERVAL: Products containing aluminum, calcium, iron, magnesium, zinc and other polyvalent cations such as antacids or mineral supplements can significantly… | 4 sources — open the full entry |
| EsomeprazolebaseMUPS preparationvia Iron | Moderate | Absorption | The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent… | 12 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycinvia Iron, Folic acid | Moderate | Absorption · Unknown | The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent…3 documented mechanisms | 12 sources — open the full entry |
| Ethosuximidevia Folic acid | Moderate | Antagonism | Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair… | 26 sources — open the full entry |
| Ferric Carboxymaltosevia Iron | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Ferric Derisomaltosevia Iron | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Ferric Pyrophosphate Citratevia Iron | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Fosphenytoin Sodiumvia Folic acid | Moderate | Antagonism | Anticonvulsants including, but not limited to, carbamazepine, lamotrigine, phenobarbital, phenytoin, primidone, and valproic acid have been shown to impair… | 26 sources — open the full entry |
| Gatifloxacinvia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…2 documented mechanisms | 32 sources — open the full entry |
| Gatifloxacin + Dexamethasonevia Iron, Folic acid | Moderate | Absorption · Unknown | INTERVAL: Oral preparations that contain magnesium, aluminum, or calcium may significantly decrease the gastrointestinal absorption of quinolone antibiotics…3 documented mechanisms | 32 sources — open the full entry |
Food & lifestyle
alcohol
ModerateSynergy
Ethanol may increase folic acid elimination and folic acid absorption is decreased in chronic alcoholics. Excessive alcohol consumption may lead to folate deficiency.
What to do: Monitoring of patient response to folic acid supplementation if they also consume alcohol regularly may be recommended.
5 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- Agencia Espa?ola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaci��n online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html" (2008):
- Cerner Multum, Inc "ANVISA Bul��rio Eletr?nico." O 0 (2015):
- "Product Information. Folic Acid (folic acid)." Method Pharmaceuticals, LLC (2017):
food
ModerateAbsorption
Concomitant use of some food may reduce the bioavailability of orally administered iron, and vice versa.
What to do: Ideally, iron products should be taken on an empty stomach (i.e., at least 1 hour before or 2 hours after meals), but if this is not possible, administer with meals and monitor the patient more closely for a subtherapeutic effect. Some studies suggest administration of iron with ascorbic acid may enhance bioavailability. In addition, administration of oral iron products and some oral medications should be separated whenever the bioavailability of either agent may be decreased. Consult the product labeling for specific separation times and monitor clinical responses as appropriate.
2 sources
- "Product Information. Feosol (ferrous sulfate)." SmithKline Beecham
- "Product Information. Accrufer (ferric maltol)." Shield Therapeutics (2021):
Conditions
Conditions in which Iron + Folic Acid + Vitamin A + Vitamin C + Zinc needs care, as documented in this source.
Anemia
MajorThe use of folic acid is contraindicated in patients with undiagnosed anemia. Folic acid in dosages above 1 mg/day can obscure the diagnosis of pernicious anemia by alleviating the hematologic abnormalities while allowing the progression of neurologic complications. In addition, folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.
3 sources
- Butterworth CE Jr, Tamura T "Folic acid safety and toxicity: a brief review." Am J Clin Nutr 50 (1989): 353-8
- Katz M "Potential danger of self-medication with folic acid." N Engl J Med 289 (1973): 1095
- "Product Information. Renal Multivitamin Formula Rx (folic acid)." Vitaline Corporation, Ashland, OR.
Liver Diseases
MajorVitamin A (including beta-carotene) is fat soluble and requires bile for adequate intestinal absorption. Hepatic and/or biliary dysfunction decrease the absorption of vitamin A. Vitamin A is metabolized by the liver and primarily excreted in bile and feces. Beta-carotene is primarily metabolized in the GI mucosa to vitamin A. Hepatic and/or biliary impairment can alter the metabolic and therapeutic activity of Vitamin A.
1 source
- "Product Information. Aquasol A (vitamin A)." Hospira Inc (2022):
Malabsorption Syndromes
ModerateAbsorption of vitamin A depends on the presence of bile and absorbable fat in the GI tract. Prolonged fat malabsorption (cystic fibrosis, hepatic cirrhosis, sprue) or malabsorption syndromes (celiac disease, GI resection) can decrease the absorption of Vitamin A. Water- miscible vitamin A formulations may be an appropriate alternative in malabsorption conditions for certain conditions requiring vitamin A therapy.
1 source
- "Product Information. Aquasol A (vitamin A)." Hospira Inc (2022):